Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -42,607 | -190,886 | -152,076 | -110,676 | -59,733 |
| Depreciation Amortization | 1,984 | 8,138 | 5,902 | 3,728 | 1,793 |
| Accounts payable and accrued liabilities | 663 | -1,231 | -1,830 | -758 | -336 |
| Other Working Capital | 18,371 | -10,877 | -10,675 | -10,530 | -8,294 |
| Other Operating Activity | 8,676 | 45,610 | 37,032 | 26,277 | 13,641 |
| Operating Cash Flow | $-12,913 | $-149,246 | $-121,647 | $-91,959 | $-52,929 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -386 | -386 | -143 | -99 |
| Purchase Of Investment | -101,694 | -138,257 | -109,880 | -60,146 | -50,225 |
| Sale Of Investment | 72,115 | 234,202 | 172,212 | 110,300 | 56,500 |
| Investing Cash Flow | $-29,588 | $95,559 | $61,946 | $50,011 | $6,176 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 21,122 | 23,249 | 15,390 | 12,154 | 10,640 |
| Other Financing Activity | 0 | 6,908 | 6,908 | 6,908 | 3,350 |
| Financing Cash Flow | $21,122 | $30,157 | $22,298 | $19,062 | $13,990 |
| Beginning Cash Position | 61,980 | 85,510 | 85,510 | 85,510 | 85,510 |
| End Cash Position | 40,601 | 61,980 | 48,107 | 62,624 | 52,747 |
| Net Cash Flow | $-21,379 | $-23,530 | $-37,403 | $-22,886 | $-32,763 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,913 | -149,246 | -121,647 | -91,959 | -52,929 |
| Capital Expenditure | -9 | -386 | -386 | -143 | -99 |
| Free Cash Flow | -12,922 | -149,632 | -122,033 | -92,102 | -53,028 |